Discuss This Drug

oritavancin

CHEBI:CHEBI_82699

Definition

A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.

Chemical Information

Molecular Formula
C86H97Cl3N10O26
Molecular Mass
1793.10100
Charge
0
SMILES
CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O[C@H]5C[C@](C)(N)[C@@H](O)[C@H](C)O5)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)[C@@H](O)[C@H](C)O1)c(Cl)c2
InChI
InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
InChIKey
VHFGEBVPHAGQPI-LXKZPTCJSA-N

Alternative Names

  • (4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin
  • (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin
  • Chlorobiphenyl-chloroeremomycin
  • LY333328

Treatment Applications

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

core#notation
CHEBI:82699
DRON_00010000
1547611
oboInOwl#hasDbXref
Wikipedia:Oritavancin

Additional References

Wikipedia:Oritavancin

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

core#notation
CHEBI:82699
pharm_class_moa
Cytochrome P450 2D6 Inducers [MoA]
pharm_class
Lipoglycopeptides [CS]
pharm_class_epc
Lipoglycopeptide Antibacterial [EPC]
pharm_class_cs
Lipoglycopeptides [CS]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
1547611
oboInOwl#hasDbXref
Wikipedia:Oritavancin
oboInOwl#hasAlternativeId
CHEBI:29553
oboInOwl#id
CHEBI:82699
generic_name
oritavancin diphosphate
rxcui
2532366
product_type
DRUG FOR FURTHER PROCESSING
marketing_category
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20241231
marketing_start_date
20140901
package_marketing_start_date
23-MAR-21
active_ingredient_strength
1200 mg/40mL
nui
M000640741
route
INTRAVENOUS
dosage_form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
labeler_name
Melinta Therapeutics, LLC
brand_name
Kimyrsa
brand_name_base
Kimyrsa
product_ndc
68225-121
application_number
NDA214155
manufacturer_name
Melinta Therapeutics, LLC
spl_id
6e583f45-aea2-465d-a976-cceaef3f7d9a
active_ingredient_name
ORITAVANCIN DIPHOSPHATE
package_ndc
68225-121-00
package_description
51 VIAL in 1 BOX (68225-121-00) / 40 mL in 1 VIAL
unii
VL1P93MKZN
spl_set_id
5e755c40-6e73-4572-b474-4d8a131693d1
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_36047
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
chebi#has_functional_parent
http://purl.obolibrary.org/obo/CHEBI_47724
rdf-schema#range
https://w3id.org/def/predibionto#has_drug_110736
rdf-schema#domain
https://w3id.org/def/predibionto#has_side_effect36202
owl#annotatedSource
t304121
owl#someValuesFrom
t2995994